MOD GRF 1-29 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
=== Reagent addition === Microscale reactions performed in droplet-based applications conserve reagents and reduce reaction time all at kilohertz rates. Reagent addition to droplet microreactors has been a focus of research due to the difficulty of achieving reproducible additions at kilohertz rates without droplet-to-droplet contamination.
=== Coiled coil filament === To improve the efficiency of the lamp, the filament usually consists of multiple coils of coiled fine wire, also known as a coiled coil. Light bulbs using coiled coil filaments are sometimes referred to as double-coil bulbs. For a 60-watt 120-volt lamp, the uncoiled length of the tungsten filament is usually 580 millimetres (22.8 in), and the filament diameter is 0.046 millimetres (0.0018 in). The advantage of the coiled coil is that there is less flow of gas in the bulb along the surface of the filament wire itself. Instead, gas only flows around the outside of whole coiled coil form, reducing both evaporation of the material and heat loss from the wire. The coiled-coil filament evaporates more slowly than a straight filament of the same surface area and light-emitting power, meaning the bulb lasts longer. The increased heat retained in the filament means that it runs hotter, which results in a more efficient light source.
Minerals are the exogenous chemical elements indispensable for life. Although the four elements carbon, hydrogen, oxygen, and nitrogen (CHON) are essential for life, they are so plentiful in food and drink that these are not considered nutrients and there are no recommended intakes for these as minerals. The need for nitrogen is addressed by requirements set for protein, which is composed of nitrogen-containing amino acids. Sulfur is essential, but again does not have a recommended intake. Instead, recommended intakes are identified for the sulfur-containing amino acids methionine and cysteine. The essential nutrient trace elements for humans, listed in order of recommended dietary allowance (expressed as a mass), are potassium, chloride, sodium, calcium, phosphorus, magnesium, iron, zinc, manganese, copper, iodine, chromium, molybdenum, and selenium. Additionally, cobalt is a component of vitamin B12 which is essential. There are other minerals which are essential for some plants and animals, but may or may not be essential for humans, such as boron and silicon.
The extent to which psilocin (and by extension psilocybin) is metabolized by MAO, specifically MAO-A, is not fully clear, but has ranged from 4% to 33% in different studies based on metabolite excretion. However, circulating levels of the deaminated metabolite of psilocin are far higher than those of free unmetabolized psilocin with psilocybin administration. An early clinical study of psilocybin in combination with short-term tranylcypromine pretreatment found that tranylcypromine marginally potentiated the peripheral effects of psilocybin, including pressor effects and mydriasis, but overall did not significantly modify the psychoactive and hallucinogenic effects of the psilocybin, although some of its emotional effects were said to be reduced and some of its perceptual effects were said to be amplified. Some psychedelics are substrates of cytochrome P450 (CYP450) enzymes, for instance LSD being a substrate of CYP2D6 as well as of several other CYP450 enzymes. As such, CYP450 inhibitors may increase exposure to CYP450-substrate psychedelics such as LSD and thereby potentiate their effects as well as risks. A clinical study found that administration of LSD to people taking paroxetine, a selective serotonin reuptake inhibitor (SSRI) and strong CYP2D6 inhibitor, increased LSD exposure by about 1.5-fold. The combination was well-tolerated and did not modify the pleasant subjective effects or physiological effects of LSD, whereas negative effects of LSD, including "bad drug effect", anxiety, and nausea, were reduced.
The epithelial cells of the parathyroid glands are richly supplied with blood from the Inferior thyroid artery and superior thyroid artery. Parathyroid hormone acts on bone, the kidneys, and the GI tract to increase calcium reabsorption and phosphate excretion. In addition, it also stimulates the conversion of vitamin D to its most active variant, 1,25-dihydroxyvitamin D3, which further stimulates calcium absorption in the GI tract. The pancreas contains nearly 1 to 2 million pancreatic islets the organ's endocrine cells that secrete hormones, and acini. The acini secrete digestive enzymes. The pancreatic endocrine cells include alpha cells that produce and secrete the glucagon to maintain homeostatic blood sugar. In response to low blood sugar levels, the release of glucagon stimulates glycogen stores in the liver to release sugar into the bloodstream to raise blood sugar to normal levels. Pancreatic beta cells make up 60% of the cells in the islets. Along with alpha cells, beta cells help to maintain glucose levels in the body. In response to high blood sugar, beta cells secrete insulin, a hypoglycemic hormone. Insulin decreases blood glucose level by helping cells to take up and metabolize glucose, and by stopping the liver from releasing more glucose. Insulin also performs other metabolic functions: causing muscle cells to take up amino acids, and inhibiting the breakdown and release of fats. Delta cells (5%) in the islets produce regulatory somatostatin.
Sources: en.wikipedia.org
black tar heroin cannabis datura and other Solanaceae (formerly smoked to treat asthma) opium salvia divinorum tobacco possibly other plants (see the section below) Substances (also not necessarily psychoactive plants smoked within them):
When the upper plate was connected to the negative pole of the battery and the lower plate to the positive pole, the glowing patch moved downwards, and when the polarity was reversed, the patch moved upwards.
== History == Dihydroergotamine was synthesized by Albert Hofmann and Werner Stoll at Sandoz in 1943. It was first described in the scientific literature that same year. Dihydroergotamine was first approved for medical use under the brand name D.H.E. 45 in 1946. Dihydroergotamine is derived from ergot, a fungus that grows on rye and other grains.
==== Honeydew honey ==== Honeydew honey is made from bees taking direct secretions from trees such as pine, fir, chestnut, and oak or primarily honeydew, the sweet secretions of aphids or other plant-sap-sucking insects, to produce honey rather than from nectar. This honey has a much larger proportion of indigestibles than light floral honeys, thus causing dysentery to the bees. Honeydew honey has a stronger and less sweet flavor than nectar-based honey, and European countries have been the primary market for honeydew honey. In Greece, pine honey, a type of honeydew honey, constitutes 60–65% of honey production.
Aristotle is saying that at this stage the body is still growing; it is best for sexual activity to begin when its growth is 'no longer abundant', for when the body is more or less at full height, the transformation of nourishment into semen does not drain the body of needed material." Additionally, "Aristotle tells us that the region round the eyes was the region of the head most fruitful of seed ("most seedy" σπερματικώτατος), pointing to generally recognised effects upon the eyes of sexual indulgence and to practices which imply that seed comes from liquid in the region of the eyes." This may be explained by the belief of the Pythagoreans that "semen is a drop of the brain [τὸ δε σπέρμα εἶναι σταγόνα ἐγκέφαλου]." Greek Stoic philosophy conceived of the Logos spermatikos ("seminal word") as the principle of active reason that fecundated passive matter. The Jewish philosopher Philo similarly spoke in sexual terms of the Logos as the masculine principle of reason that sowed seeds of virtue in the feminine soul. The Christian Platonist Clement of Alexandria likened the Logos to physical blood as the "substance of the soul", and noted that some held "that the animal semen is substantially foam of its blood". Clement reflected an early Christian view that "the seed ought not be wasted nor scattered thoughtlessly nor sown in a way it cannot grow." Women were believed to have their own version, which was stored in the womb and released during climax. Retention was believed to cause female hysteria.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.